MAK Capital

MARAbio is a biotech company focused on detecting and preventing severe autism through maternal autoantibody-related autism testing. The company's precision technology identifies a distinctive cluster of antibodies directed against brain proteins in mothers whose children have autism spectrum disorder, enabling early risk assessment and the initiation of targeted behavioral therapies as developmental delays emerge.

Noveome Biotherapeutics is a clinical-stage biotherapeutics company focused on regenerative repair of inflamed or damaged tissues. It develops multi-component biologic therapies at physiological concentrations that work together to provide anti-inflammatory, neuroprotective, anti-apoptotic, and preservation of vascular integrity effects. The lead program centers on ST266, a secretome-based product that modulates inflammation, accelerates wound healing, promotes bone restoration, restores nerve function, and supports tissue regeneration.

Trailhead Biosystems specializes in developing cell therapy technologies by integrating hardware, software services, developmental biology, and cell therapeutics. The company optimizes process-specific parameters for clients to efficiently develop cell therapies.